Policy & Regulation
Recipharm announces new financial targets for 2020 on Capital Markets Day
19 November 2019 -

Recipharm AB (STO:RECIB), a Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry, reported on Monday new financial targets for 2020, as the company has continued to grow.

These new financial targets are achieving a Compound Annual Growth Rate (CAGR) of at least 11%, with 2019 as base year, with the growth being organic as well as coming from acquisitions; achieving an EBITA margin of at least 12% each year, measured as profit before financial items, tax and amortisation of intangible assets attributable to acquisitions, adjusted for non-recurring items and in relation to net sales and achieving a return on operating capital of 10%, defined as EBITA divided by operating capital.

The company will present its strategy for profitable growth moving forward, together with new financial targets from 2020, at Capital Markets Day in Stockholm on 18 November 2019.

Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies.